Search Results

LFM-A13 10 mg  | 99.90%

TargetMol

LFM-A13（IC50=2.5 μM）, a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.

More Information Supplier Page

LFM-A13 25 mg  | 99.90%

TargetMol

LFM-A13（IC50=2.5 μM）, a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.

More Information Supplier Page

LFM-A13 50 mg  | 99.90%

TargetMol

LFM-A13（IC50=2.5 μM）, a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.

More Information Supplier Page

LFM-A13 5 mg  | 99.90%

TargetMol

LFM-A13（IC50=2.5 μM）, a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.

More Information Supplier Page

CP-466722 10 mg  | 99.85%

TargetMol

CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.

More Information Supplier Page

CP-466722 2 mg  | 99.85%

TargetMol

CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.

More Information Supplier Page

CP-466722 50 mg  | 99.85%

TargetMol

CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.

More Information Supplier Page

Darapladib 10 mg  | 100.00%

TargetMol

Darapladib(IC50=0.25 nM) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2).

More Information Supplier Page

CP-673451 5 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page

CP-673451 50 mg  | 99.93%

TargetMol

CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.

More Information Supplier Page